A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2022 Apr 23

PMID 35458385

Authors

Qianyu Duan

Shuai Xia

Fanke Jiao

Qian Wang

Rui Wang

Lu Lu

Shibo Jiang

Wei Xu

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by infection of SARS-CoV-2 and its variants has posed serious threats to global public health, thus calling for the development of potent and broad-spectrum antivirals. We previously designed and developed a peptide-based pan-coronavirus (CoV) fusion inhibitor, EK1, which is effective against all human CoVs (HCoV) tested by targeting the HCoV S protein HR1 domain. However, its relatively short half-life may limit its clinical use. Therefore, we designed, constructed, and expressed a recombinant protein, FL-EK1, which consists of a modified fibronectin type III domain (FN3) with albumin-binding capacity, a flexible linker, and EK1. As with EK1, we found that FL-EK1 could also effectively inhibit infection of SARS-CoV-2 and its variants, as well as HCoV-OC43. Furthermore, it protected mice from infection by the SARS-CoV-2 Delta variant and HCoV-OC43. Importantly, the half-life of FL-EK1 (30 h) is about 15.7-fold longer than that of EK1 (1.8 h). These results suggest that FL-EK1 is a promising candidate for the development of a pan-CoV fusion inhibitor-based long-acting antiviral drug for preventing and treating infection by current and future SARS-CoV-2 variants, as well as other HCoVs.

Citing Articles

FEOpti-ACVP: identification of novel anti-coronavirus peptide sequences based on feature engineering and optimization.

Jiang J, Pei H, Li J, Li M, Zou Q, Lv Z Brief Bioinform. 2024; 25(2).

PMID: 38366802 PMC: 10939380. DOI: 10.1093/bib/bbae037.

IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies.

Su X, Huang Z, Xu W, Wang Q, Xing L, Lu L Biomolecules. 2023; 13(9).

PMID: 37759683 PMC: 10526447. DOI: 10.3390/biom13091283.

Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines.

Guo L, Lin S, Chen Z, Cao Y, He B, Lu G Signal Transduct Target Ther. 2023; 8(1):197.

PMID: 37164987 PMC: 10170451. DOI: 10.1038/s41392-023-01472-x.

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.

Xia S, Wang L, Jiao F, Yu X, Xu W, Huang Z Emerg Microbes Infect. 2023; 12(1):2178241.

PMID: 36748716 PMC: 9970205. DOI: 10.1080/22221751.2023.2178241.

Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.

Lan Q, Wang L, Jiao F, Lu L, Xia S, Jiang S J Med Virol. 2022; 95(1):e28143.

PMID: 36098460 PMC: 9539121. DOI: 10.1002/jmv.28143.

References

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Woo P, Lau S, Lam C, Lau C, Tsang A, Lau J . Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and.... J Virol. 2012; 86(7):3995-4008. PMC: 3302495. DOI: 10.1128/JVI.06540-11. View

Walker A, Dunlevy G, Rycroft D, Topley P, Holt L, Herbert T . Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng Des Sel. 2010; 23(4):271-8. DOI: 10.1093/protein/gzp091. View

Li W, Moore M, Vasilieva N, Sui J, Wong S, Berne M . Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965):450-4. PMC: 7095016. DOI: 10.1038/nature02145. View

Su S, Wang Q, Jiang S . Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad-spectrum, and safe COVID-19 vaccines and therapeutics. Clin Transl Med. 2021; 11(1):e284. PMC: 7803365. DOI: 10.1002/ctm2.284. View

Koide A, Bailey C, Huang X, Koide S . The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol. 1998; 284(4):1141-51. DOI: 10.1006/jmbi.1998.2238. View

Bi W, Xu W, Cheng L, Xue J, Wang Q, Yu F . IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. PLoS Pathog. 2019; 15(12):e1008082. PMC: 6894747. DOI: 10.1371/journal.ppat.1008082. View

Gapizov S, Petrovskaya L, Shingarova L, Kryukova E, Boldyreva E, Lukashev E . Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein. Biotechnol Appl Biochem. 2019; 66(4):617-625. DOI: 10.1002/bab.1762. View

Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q . A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm Sin B. 2021; 12(4):1652-1661. PMC: 8327648. DOI: 10.1016/j.apsb.2021.07.026. View

10.

Xia S, Chan J, Wang L, Jiao F, Chik K, Chu H . Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Res. 2022; 32(4):404-406. PMC: 8793821. DOI: 10.1038/s41422-022-00617-x. View

11.

Su S, Rasquinha G, Du L, Wang Q, Xu W, Li W . A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. Molecules. 2019; 24(6). PMC: 6470885. DOI: 10.3390/molecules24061134. View

12.

Luytjes W, Sturman L, Bredenbeek P, Charite J, van der Zeijst B, Horzinek M . Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site. Virology. 1987; 161(2):479-87. PMC: 7130946. DOI: 10.1016/0042-6822(87)90142-5. View

13.

Bosch B, van der Zee R, de Haan C, Rottier P . The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003; 77(16):8801-11. PMC: 167208. DOI: 10.1128/jvi.77.16.8801-8811.2003. View

14.

Bosch B, Martina B, van der Zee R, Lepault J, Haijema B, Versluis C . Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci U S A. 2004; 101(22):8455-60. PMC: 420415. DOI: 10.1073/pnas.0400576101. View

15.

Chong H, Xue J, Zhu Y, Cong Z, Chen T, Wei Q . Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. PLoS Pathog. 2019; 15(2):e1007552. PMC: 6375636. DOI: 10.1371/journal.ppat.1007552. View

16.

Lipovsek D . Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel. 2010; 24(1-2):3-9. PMC: 3003446. DOI: 10.1093/protein/gzq097. View

17.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View

18.

Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M . Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerg Microbes Infect. 2022; 11(1):477-481. PMC: 8820826. DOI: 10.1080/22221751.2022.2030200. View

19.

Koide A, Wojcik J, Gilbreth R, Hoey R, Koide S . Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J Mol Biol. 2011; 415(2):393-405. PMC: 3260337. DOI: 10.1016/j.jmb.2011.12.019. View

20.

Bloom L, Calabro V . FN3: a new protein scaffold reaches the clinic. Drug Discov Today. 2009; 14(19-20):949-55. DOI: 10.1016/j.drudis.2009.06.007. View